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ABSTRACT
 HIV-1 infection is a serious condition affecting approximately 37 million 
individuals. Between 30% and 60% of seropositive individuals will develop symptoms of 
clinical depression. These individuals are five times more likely to commit suicide than 
non-seropositive clinically depressed patients. Dysfunction in serotonergic and 
dopaminergic transmission has consistently been implicated in the pathogenesis of 
depression. Specifically, dysfunction in the prefrontal cortex and in the nucleus 
accumbens core region have been shown to be underlying factors in the trajectory of 
depression. Given these underlying neurological features, the present research employed 
behavioral testing and electrochemical recording in an attempt to elucidate the 
therapeutic efficacy of the SSRI escitalopram in treating HIV-1 mitigated depressive 
symptoms in a transgenic (Tg) rodent model of depression. The HIV-1 Tg rat contains 
seven of the nine genes present in the HIV viral genome and presents itself with 
impairments similar to those observed in human HIV-1 seropositive individuals. The 
HIV-1 Tg rat thus represents a non-infectious model for controlled HIV-1 exposure. 
Here, we report failure of the SSRI to attenuate behavioral and electrochemical 
alterations present in the HIV-1 Tg rat. Given the known variability of SSRI medication 
and previously documented individual differences to drug dosage found within the 
model, it is thus concluded that more research is required in order to firmly establish the 
global efficacy of escitalopram in treated comorbid HIV-1 clinical depression. 
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CHAPTER 1 
INTRODUCTION 
HIV is a serious condition affecting approximately 37 million people worldwide 
as of 2017. Consequently, the condition is estimated to affect roughly 0.8% of adults ages 
15-49 (World Health Organization, 2017). In that same year, approximately 37,000 new 
cases were estimated to have occurred, many of which remained unknown to affected 
individuals (World Health Organization, 2017). While the advent of combination 
antiretroviral therapy (cART) has dramatically increased the prospects of living with 
HIV, individuals affected still suffer from deficits associated with the condition. 
Adherence to cART has the potential to reduce the viral load in the periphery, though the 
virus still persists in the central nervous system (Bertrand et al.,2013). HIV is 
neuroinvasive and invades the nervous system rapidly after initial exposure, where it 
principally infects microglia. The neurovirulent effects of HIV infection often include 
neuropathy, dementia, myopathy, and myelopathy (Silvers et al., 2006).  
In the United States, an estimated 30-60% of HIV-infected persons will develop 
some degree of clinical depression over the course of their lifetime (Bhatia and Munjal, 
2014, Castellon et al., 1998). Moreover, the prevalence of suicide among such infected 
individuals is three to five times higher than individuals not affected with HIV, despite 
treatment for antiretroviral therapy (US Department of Veterans Affairs, 2009). Apathy, a 
distinct but highly correlated condition, also remains a common psychiatric disturbance 
among HIV infected individuals. This alarming comorbid prevalence is however 
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unsurprising given the well-documented relationship between apathy and depression 
(Castellon, et al., 1998; Marin, Firinciogullari, and Biedrzycki, 1993). In addition to 
depression and apathy, approximately 50% of seropositive individuals will develop some 
degree of HIV-associated neurocognitive disorder (HAND) despite adherence to cART. 
(Sanmarti, 2014 Bryant et al., 2015).  
 The development of apathy is attributed directly to the effects of viral infection, 
specifically to the consequent expression of the neurotoxic proteins Tat and gp120. These 
proteins are hypothesized to produce deleterious effects upon the dopaminergic system 
and the neural circuitry underlying reward pathways (McIntosh et al., 2015). The 
alarming of degree of dopaminergic dysfunction present during HIV infection has been 
extensively documented in both clinical and pre-clinical literature (Aksenov et al., 2008; 
Bertrand et al., 2013; Ferris, Mactutus, and Booze, 2008; Fitting et al., 2008; Fitting et 
al., 2015; Javadi-Paydar et al., 2017; Nath et al., 2000; Paris et al., 2014; Purohit, Rapaka, 
and Shurtleff, 2011; Roscoe, Mactutus and Booze, 2014; Silvers et al., 2006; Zhu et al., 
2009; Denton et al., forthcoming).  
The dynamic relationship between HIV-1 and clinical depression has enjoyed 
little consideration within the literature, however, as many reports have failed to produce 
prospects for any effective treatment regimes. To this end, the present work sought to 
examine the effects of treatment with escitalopram to the HIV-1 Transgenic (Tg) rat. The 
HIV-1 Tg rat contains 7 of the constituent 9 genes that comprise the HIV viral genome, 
resulting in a non-infectious, long-term model of HIV-1 viral protein exposure, which is 
an effective model of HIV seropositive individuals adhering to long term cART 
treatment. (Reid et al., 2001; Vigorito et al., 2015 McLaurin et al., 2018). The HIV-1 Tg 
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rat are produced using an infectious provirus derivation following deletion of the Sph1-
Bal1 fragment that encompasses the gag and pol genes of the virus, rendering the model 
non-infectious. Production of proteins such as the deleterious tat and gp120 remain under 
the control of the LTR promoter resulting in protein expression that is thought to 
undermine monoamine function (Reid et al., 2001; Bertrand et al., 2018; Denton et al., 
forthcoming).The HIV-1 Tg rat has previously demonstrated compromised 
synaptodentric connectivity in the nucleus accumbens core region, in addition to 
compromised rates of dopaminergic and serotonergic function in the nucleus accumbens 
core and prefrontal cortex, respectively (Roscoe et al., 2014; Denton et al., forthcoming).  
Escitalopram is a selective serotonin reuptake inhibitor marketed under the trade 
name Lexapro and is commonly prescribed to individuals suffering from depression. 
Moreover, the Veteran’s affairs administration considers escitalopram to be a safe 
accompaniment to cART therapy (US Department of Veterans Affairs, 2009). Thus, the 
present study sought to directly examine the effects of escitalopram treatment upon a 
behavioral testing battery comprised of five tasks commonly used to gauge depressive 
symptoms in rodent research, followed by examining the real-time release and reuptake 
kinetics of serotonin and dopamine as measured by fast-scan cyclic voltammetry (FSCV). 
For the present purposes, a five bottle sucrose concentration task, modified hole board 
task, elevated plus maze task, pre-pulse inhibition (PPI) of the visual and acoustic startle 
task and a social behavior task were used to evaluate the behavioral effects of 
escitalopram treatment in HIV-1 Tg versus F344/N rats. 
Sucrose preference testing in rodents is used to gauge levels of anhedonia. Rats 
naturally consume sweet solutions as a preference over unsweet solutions. Decreased 
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consumption of a mixture of sucrose and water relative to consumption of distilled water 
alone is a behavioral marker indicative of anhedonic behavior in rodents (Serchov, Calker 
and Biber, 2016). Moreover, sucrose preference testing has previously been employed in 
studying the HIV-1 Tg rat (Bertrand et al., 2018). Anhedonia is classically considered a 
core symptom of clinical depression (Nestler, 2002). The modified hole board task 
gauges exploratory behavior – an indication of anxiolytic and depressive symptoms in 
rats (Takeda, Tsuji and Matsumiya, 1998). Such symptoms are known to be present if 
fewer hole pokes are performed by a rodent relative to age matched control animals. 
Nose pokes into the holes of the apparatus are recorded via photocells positioned 
underneath the platform. Pre-pulse inhibition of the acoustic and visual startle are 
commonly used in depression research in both human and pre-clinical populations (Perry 
et al., 2004; Fletcher et al., 2001). Moreover, previous research has demonstrated that the 
HIV-1 Tg rat possesses significant deficits in pre-pulse inhibition (Moran et al., 2013; 
McLaurin et al., 2017 McLaurin et al., 2018). The elevated plus maze measures 
exploratory behavior as a ratio of the time the rodent spends on an open and exposed arm 
of the maze versus time spent in closed locations of the maze . Greater time spent in 
closed locations of indicative of heightened levels of anxiety and depressive behaviors 
(Pellow, et al.,1985). Total time spent in each arm is recorded with behavioral tracking 
software. Social interaction is considered to be a measure of anxiety in rodents, and has 
previously been employed in antidepressant research (Griebel et al., 1994; Dekeyne et al., 
2000; Rodiguez-Porcel, 2001). 
Fast Scan Cyclic Voltammetry (FSCV) is an electrochemical technique that 
allows for the rapid detection of a broad range of chemical species. FSCV is a more 
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specialized form of cyclic voltammetry in which a considerably higher scan rate is 
employed allowing for the rapid acquisition of an individual voltammogram. Thus, the 
technique has a considerable temporal resolution. FSCV enjoys a competitive advantage 
over other available techniques in that concentration of the target analyte is observed in 
real-time, with quantification of the target analyte occurring rapidly. Moreover, positive 
identification of the target analyte is provided via the cyclic voltammogram produced 
throughout the recording period (Robinson, et. al, 2003). 
 FSCV involves the application of a triangular waveform within a target analyte 
specific voltage range to an electrode. The resting potential is held at a voltage that is 
insufficient to oxidize the target analyte, then rapidly increased at a high scan rate to a 
target potential to promote oxidation. This oxidation produces a detectable electrical 
current. The potential is then returned to starting potential, thus produce a detectable 
change in electrical current in the opposite direction. This cycle of oxidation and 
reduction produces time-resolved peaks that allow for the quantification of the target 
analyte. 
 The technique was initially developed by Mark Wightman in the 1980’s, and first 
used to characterize dopaminergic transmission and reuptake in the caudate nucleus of 
the rat (Millar et. al, 1985). Since this initial development, FSCV has enjoyed a wide 
range of application to the study of dopaminergic transmission in single cells, brain 
slices, anesthetized animals, freely moving animals, and even awake and behaving 
animals (Budygin, et. al, 2001; Kelly and Wightman, 1987; Kuhr, Wightman and Rebec, 
1987; Millar et al., 1985; Phillips et. al, 2003; Robinson et. al, 2003; Troyer and 
Wightman, 2002). 
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 While the quantification of dopamine with FSCV enjoyed a long history of 
consistent replication, quantification of serotonin did not occur until much more recently. 
The first in-vivo recording of 5-hydroxytryptamine (5-HT or serotonin) in the 
mammalian brain occurred as recently as 2009 (Hashemi et. al, 2009). This was achieved 
through modification to the standard carbon fiber electrode with Nafion, a cation 
exchange polymer. While the oxidation of dopamine to dopamine-o-quinone is a 
relatively clean and predictable process, the oxidation of serotonin produces by-products 
that polymerize and permanently coat the surface of the carbon fiber microelectrode 
(Hashemi et. al, 2009). The Nafion coating prevents the by-products of oxidation from 
damaging the surface of the electrode (Hashemi et. al, 2009).
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 ETHICS STATEMENT 
 Experiments were conducted in accordance with the recommendations listed in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health.  The research protocols were approved by the Institutional Animal Care and Use 
Committee at the University of South Carolina (assurance number: D16-00028). 
2.2 SUBJECTS 
 Animals (n=73; HIV-1 Tg=31, F344/N=42) were obtained from Envigo, 
(Indianapolis, IN) and pair housed under targeted conditions of 21°±2 °C, 50 %±10 % 
relative humidity with a 12 hour light: dark cycle.. Animals were pair housed by both sex 
and genotype. Food (Pro-Lab Rat, Mouse, and Hamster chow # 3000) and water were 
available ad libitum throughout the duration of the experiment. All behavior tasks were 
conducted during diurnal hours. 
2.3 DRUG TREATMENT 
 Escitalopram (4 mg/kg for 40 days) (Sigma Aldrich, Saint Louis, MO) or placebo 
pellets (Innovative Research of America, Sarasota, FL) were subcutaneously implanted in 
the medial neck area of each animal. Animals were anesthetized using a 2-3% 
concentration of sevoflurane. Fur was removed from the target area and a small 
(approximately 3 mm) incision was made into which the pellet was placed. Incisions 
were then sutured and each animal was administered a bodyweight dependent dose of 
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butorphanol and placed in a recovery chamber with a heating pad. Animals were returned 
to their home cages after full locomotor recovery occurred. Animals were monitored for 
one week in post-operative care before beginning behavioral testing. Animal body weight 
and well-being were monitored daily to ensure compliance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health.   
2.4 ESTROUS CYCLE TRACKING 
 Vaginal lavage was performed on each day of the testing period to determine 
cycle stage of female rodents. Each lavage was performed with approximately 1 mL of 
freshly prepared phosphate-buffered solution. The solution was administered to the 
vagina of the rat with a standard eye dropper and quickly retracted. The solution was then 
evaluated under a low-power light microscope to determine cycle stage (Booze et 
al.,1999; Westwood, 2008). 
2.5 SUCROSE PREFERENCE  
 Animals were individually placed in an empty testing chamber with free access to 
0%, 1%, 5%, 10% and 30% concentrations of sucrose solution in 100 ml graduated 
cylinders equipped with stopper and drinking tube (Ancare, Bellmore, NY). Habituation 
to the five bottle presense occurred two consecutive days prior to testing period. 
Following habituation, animals were tested for 30 minutes per day for five consecutive 
days. Sucrose consumption was measured both with respect to meniscus volume and 
cylinder weight. Cylinder order was randomized daily using a Latin square design to 
control for any effect of cylinder position upon sucrose consumption. 
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2.6 MODIFIED HOLE BOARD  
 A custom made delrin insert equipped with 16 equidistant holes was placed inside 
a 40 cm3 locomotor activity chamber. Nose pokes into each hole was recorded by 
photocells placed below the custom insert. Each nose poke was recorded by FlexField 
Software (SanDiego Instruments, San Diego CA). Recording sessions occurred for 10 
minutes each day for a period of 7 consecutive days following a 10 minute habituation 
period. The apparatus was cleaned with a 10% ethanol solution following the testing 
period. Testing was performed in the presence of 70db background white noise in a 
darkened room to encourage exploratory behavior. 
2.7 ELEVATED PLUS MAZE 
 Each animal received a single testing session in an elevated plus maze apparatus. 
Behavior was recorded by a camera mounted above the apparatus. The dependent 
measure of interest was time spent in the open arm of the apparatus versus time spent in 
the closed arm of the apparatus. Overall activity was recorded with SMART tracking 
software (San Diego Instruments, San Diego CA). The apparatus was cleaned with a 10% 
ethanol solution between consecutive trials. Female animals were tested while in diestrus 
to control for any effect of estrus hormonal cycle upon exploratory animal. Failed trials 
(e.g. animal falling from apparatus) were retested one week later. This time in between 
trials was used to ensure no effect of learning/habituation upon subsequent plus maze 
trials. 
2.8 PREPULSE INHIBITION OF ACOUSTIC AND VISUAL STARTLE 
 Animals were placed in a startle chamber (SR-Lab Startle Reflex System, San 
Diego Instruments) enclosed in an isolation cabinet (Industrial Acoustic Company) and 
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acclimated to the presence of 70dB background noise for a period of 5 minutes. The 
subjects were then presented with a series of six pulse-only trials at 100dB. Following 
this acclimation period, subjects were presented with 36 pre-pulse trials of 85dB with 
interstimulus intervals of 0, 8, 40, 80, 120 and 4,000 milliseconds assigned in a Latin 
square procedure. The stimulus occured for 20 milliseconds. 0 and 4000 millisecond 
intervals were included to provide a baseline acoustic startle response. The apparatus was 
cleaned thoroughly with ethanol solution between each trial. 
2.9 SOCIAL AND PLAY BEHAVIOR 
 On the day of testing, animals were habituated to the testing room for a period of 
10 minutes. Animals were then placed into an empty testing chamber with a bodyweight 
and sex matched novel partner. Rodent interaction was recorded for a period of 10 
minutes. Total interaction time was recorded as a dependent measure of social behavior. 
Females were tested in diestrus. Successive trials were conducted in previously cleaned 
cages to account for any bias due to novel smell or debris. 
2.10 MANUFACTURE OF CARBON FIBER MICROELECTRODES 
 Carbon fiber microelectrodes were manufactured by aspirating 7 µm diameter 
carbon-fibers (Goodfellow Inc, Coraopolis, PA) into glass capillaries (0.6mm external 
diameter, 0.4mm internal diameter, A-M Systems Inc., Sequim, WA). Fibers were sealed 
into the capillaries with a vertical pipette puller (Narishige Group, Tokyo, Japan). The 
exposed fiber was trimmed to approximately 150 µm under a low-light power 
microscope for evaluation of serotonin and histamine and to 50 µm for evaluation of 
dopamine. Nafion was electrodeposited onto the exposed carbon fiber portion of 
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serotonin and histamine electrodes as previously described and then dried at 70º C for 10 
minutes (Hashemi et al. 2009). 
2.11 IMPLANTATION OF CARBON FIBER MICROELECTRODES AND 
STIMULATING PIN 
Animals were deeply anesthetized using 2-4% sevoflurane. The animal’s head 
was placed into a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA.), with a 
heating pad to maintain constant body temperature. Carbon fiber microelectrodes were 
placed into the animal’s nucleus accumbens (AP: +2.6, ML: +1.6, DV: -5.8) and CA2 
region of the hippocampus (AP: -5.5, ML: +5.0, DV: -4.0), for evaluation of dopamine 
and serotonin, respectively (Paxinos and Watson, 2014). A stainless steel stimulating 
electrode (Plastics One, Roanoke VA) was implanted in the medial forebrain bundle (AP: 
-2.8, ML: +1.7, DV: -8.0), while a chloride electroplated silver reference electrode was 
placed in the hemisphere opposite the stimulating electrode. To stimulate the release of 
the neurotransmitters, biphasic pulse trains were applied through a NeuroLog linear 
constant current stimulus isolator (NL800A, Neurolog; Medical Systems Corp., Great 
Neck, NY). Background-subtracted cyclic voltammograms were obtained as time vs. 
voltage (x-axis by y-axis).  
2.12 TERMINATION (SACRIFICE) OF ANIMAL 
Following the conclusion of the recording session, animals were sacrificed under 
deep anesthesia. Brains were removed and stored in a -80ºC freezer. Animals not used for 
voltammetry were sacrificed via transcardial perfusion of approximately 100 mL of 
freshly prepared paraformaldehyde. Brains were then removed and stored in 
paraformaldehyde for further analyses. 
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2.13 BEHAVIORAL DATA ANALYSIS 
 All statistical analyses were performed using IBM SPSS (version 24) where a p-
value of less than 0.05 was considered to be statistically significant. For evaluation of 
sucrose preference, a mixed factorial ANOVA was utilized where transgene, sex and 
treatment were held as between subject factors while variable concentration of sucrose 
was held as a within-subjects factor. Similarly, a mixed factorial ANOVA was used for 
evaluation of pre-pulse inhibition where transgene, sex and treatment were held as 
between subject factors while variable inter-stimulus interval was held as a within-
subjects factor. To evaluate elevated-plus maze performance and social behavior, a 
factorial ANOVA was employed to examine the effects of treatment, sex and transgene. 
All graphs were produced with GraphPad prism (version 5). Rodent age was held as a 
covariate across all analyses. 
2.14  VOLTAMMETRIC DATA ANALYSIS 
 Recordings were obtained using customized software. LabView (Knowmad 
Technologies LLC). Color plots of the evoked chemicals were generated within the data 
analysis features of the custom software. GraphPad Prism (version 5) was used to 
produce current versus time plots for each neurotransmitter of interest. Peak 
concentrations of neurotransmitter release were analyzed using IBM SPSS (version 24) 
with a factorial ANOVA comparing factors of the transgene (HIV-1 Tg vs. F344/N) and 
sex. P-values less than or equal to 0.05 were considered statistically significant. Rates of 
release and reuptake of individual analytes were calculated using GraphPad prism where 
K, a nonlinear rate constant, was evaluated for both release and reuptake. Peak 
concentration values were obtained from the raw evoked electrical current. Female 
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rodents were evaluated during diestrus to control for any bias due to fluctuation of 
circulating hormones. All terminal sacrifices of rats were conducted during diestrus in a 
similar manner. This procedure was done in order to eliminate sources of variation for 
future analyses. 
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CHAPTER 3 
RESULTS 
3.1 SUCROSE PREFERENCE  
Escitalopram was not found to alter sucrose consumption in either HIV-1 Tg 
animals or F344/N control animals. Linear and non-linear modeling of the response to 
concentration curves revealed a transgene mediated alteration of response, with a shift in 
response to sucrose concentration occurring in HIV-1 Tg animals independent of drug 
treatment. Dose-dependent responding to sucrose concentrations proceeded in a 
logarithmic fashion for these animals, while, in contrast, dose-dependent responding in 
F344/N control animals proceeded in a linear fashion. Separate models were fit to the 
data to illustrate this finding. (All r2>75%). (Figure 3.1). 
3.2 MODIFIED HOLE BOARD AND ELEVATED PLUS MAZE 
A mixed model ANOVA was used to evaluate the effects of genotype, sex, 
treatment and their interactions upon the within-subjects factor of overall exploration 
(hole pokes, open arm exploration) (Figures 3.2 and 3.3). A significant interaction was 
found for genotype and sex with respect to exploration [F(1,71)=3.59, p≤0.05]. Rats 
treated with escitalopram explored significantly more relative to placebo treated animals 
across elevated plus maze trials. [F(1,72)=4.21, p≤0.05]. While global effects of 
escitalopram treatment were not found across both tasks together, escitalopram 
significantly increased exploration in elevated plus maze trials. Males showed the lowest 
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response to escitalopram independent of genotype across both trials, though the 
effect was not statistically significant [F(1,72)= 1.11, p=ns] 
3.3 PREPULSE INHIBITION OF ACOUSTIC AND VISUAL STARTLE 
Significant main effects of genotype were reported for both visual (Figure 3.4) 
and auditory (Figure 3.5) PPI, with HIV-1 Tg animals demonstrating significant 
impairment relative to controls [visual PPI, F(1,72)=12.12, p≤0.01; auditory PPI, 
F(1,72)=8.38, p≤0.05]. Although escitalopram treatment did appear to alter both auditory 
and visual PPI in transgenic rats, no interaction effects or other main effects were found 
to be statistically significant. HIV-1 Tg rats treated with escitalopram demonstrated 
significant visual PPI impairments relative to placebo treated animals and F344/N 
animals, suggesting a visual effect of chronic escitalopram treatment. 
3.4 SOCIAL AND PLAY BEHAVIOR 
 No significant main effects for between-subjects factors of genotype, sex or drug 
treatment. Additionally, no two-way or three way interactions were found [F(1,72)=3.83, 
p=ns]. Overall, total time in contact between rodents was stable regardless of sex, 
genotype or treatment condition (Figure 3.6).  
3.5 DOPAMINE AND SEROTONIN VOLTAMMETRY 
Decreases in peak transmission and reuptake of dopamine and serotonin were 
found in the HIV-1 Tg rat. Evoked dopamine and serotonin concentrations for HIV-1 Tg 
animals and F344 animals are displayed in figures 3.8 and 3.9 while color plots with 
respective cyclic voltammograms are displayed in figure 3.7. Maximal evoked 
concentration (Cmax) was impaired in transgenic animals across both dopamine and 
serotonin recordings. [Dopamine, F(1,9)=33.25, p≤0.001; For serotonin, F(1,16)=60.97, 
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p≤0.001]. Additionally, rates of reuptake as defined by nonlinear rate constant (k) were 
impaired in transgenic animals relative to control animals. [For dopamine, F344/N 
K=0.43, HIV-1Tg K=0.73 F(1,2634)=19.19, p≤0.001; For serotonin, F344/N K=0.37, 
HIV-1Tg K=0.56 F(1,4314)=7.308, p≤0.05. 
Increases in serotonin transmission were found in F344/N control animals treated 
with escitalopram, but not in HIV-1 Tg rodents (Figure 3.9). Rates of clearance 
(reuptake) were slower in animals treated with escitalopram (k=0.55) relative to animals 
treated with placebo (k=0.34) [F(1,4074)=9.18, p≤0.05]. While F344/N animals treated 
with escitalopram displayed a mild increase in peak evoked serotonergic potential, the 
effect was not significant [F(1,30)=0.99, p=ns] although rates of reuptake were altered for 
animals treated with escitalopram [k=0.32 vs. k=0.20 F(1,7674)=23.75, p≤0.01].  
No statistically significant differences were found for dopamine transmission in 
HIV-1 Tg rats treated with escitalopram [F(91,150)=1.00, p=ns (Figure 3.8). Evoked 
rates of maximal dopamine release were not statistically significant across a genotype by 
treatment analysis [F(1,18)=0.123, p=ns.], though HIV-animals treated with SSRI 
medication demonstrated lowest peak concentration. Rates of reuptake were not 
statistically different for HIV-1 Tg animals treated with escitalopram [(k=0.41 
F(1,1414)=0.47, p=ns], though F344/N animals treated with escitalopram demonstrated 
slower rates of reuptake than animals treated with the placebo [k=0.49 vs. k=0.23 
F(1,3834)=16.1, p≤0.001]. 
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Figure 3.1: Five bottle sucrose preference test using a 0%, 1%, 5% 10% and 30% 
concentration. No effect of drug treatment was observed independent of animal genotype 
and sex. For HIV-1 Tg animals, a curvilinear shift in response occurred between 0% and 
5% concentrations followed by a flattening of the dose-response curve between 
concentrations of 5% and 30%. F344/N animals displayed a steady linear dose response 
pattern. Separate models were fit to these data to illustrate this finding (all r2> 0.75). 
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Figure 3.2: Modified hole board performance across each treatment group. Animals were 
tested in a custom build modified hole board apparatus across seven consecutive testing 
periods. Escitalopram was not found to increase number of nose pokes independently of 
genotype or sex. Males demonstrated lowest performance overall, though the effect was 
not statistically significant. 
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Figure 3.3: Exploration time in the open arm of an elevated plus maze apparatus. Animals 
were tested during one trial for a period of ten minutes. Escitalopram was found to 
increase time spent in the open arm independently of genotype and sex (p<0.05).  
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Figure 3.4: Visual prepulse inhibition. Animals were tested during one trial following a 
habituation trial which occurred the day before. Significant impairments were found in 
HIV-1 Tg animals relative to controls (p<0.05). Escitalopram was not found to attenuate 
these deficits, however treatment did appear to alter PPI response in HIV-1 Tg rats. 
 
 
 
21 
10
100
1000
F344 Placebo
F344 Escitalopram
0 30 50 100 200 4000
Interstimulus Interval (log msec)
M
e
a
n
 P
e
a
k
 R
e
s
p
o
n
s
e
 A
m
p
li
tu
d
e
 (
lo
g
 m
s
e
c
)
 
10
100
1000
HIV-1 Tg Placebo
HIV-Tg Escitalopram
0 30 50 100 200 4000
M
e
a
n
 P
e
a
k
 R
e
s
p
o
n
s
e
 A
m
p
li
tu
d
e
 (
lo
g
 m
s
e
c
)
 
 
 
Figure 3.5: Auditory prepulse inhibition. Animals were tested during one trial following a 
habituation trial which occurred the day before. Significant impairments were found in 
HIV-1 Tg animals relative to controls (p<0.05). Similarly to visual PPI, escitalopram was 
not found to attenuate these deficits. 
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Figure 3.6: Social interaction time. Animals were tested with a novel sex and bodyweight 
matched partner in a novel cage across a ten minute trial period. Social interaction time 
was not found to be different regardless of group. No deficits in the HIV-1 Tg rat are 
present for social interaction time, and escitalopram was not found to alter interaction 
time across the trial period. 
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Table 3.1                                                                 Effect Sizes ( partial ƞ2) for Behavioral 
Effects 
3.1.1 Exploratory Behavior 
     Genotype 
 
0.04 
     Sex 0.17 
     Treatment 0.56 
     Genotype X Sex 0.48 
     Genotype X Treatment 0.04 
Sex X Treatment 0.15 
     Genotype X Treatment X Sex 0.02 
 3.1.2 Visual Pre-Pulse inhibition 
     Genotype 
 
0.19 
     Sex 0.03 
     Treatment <0.01 
     Genotype X Sex <0.01 
     Genotype X Treatment <0.01 
Sex X Treatment <0.01 
     Genotype X Treatment X Sex <0.01 
 3.1.3 Auditory Pre-Pulse inhibition 
     Genotype 
 
0.14 
     Sex 0.04 
     Treatment <0.01 
     Genotype X Sex 0.02 
     Genotype X Treatment <0.01 
Sex X Treatment <0.01 
     Genotype X Treatment X Sex <0.01 
3.1.4 Social Interaction Time 
     Genotype 
 
<0.01 
     Sex 0.02 
     Treatment <0.01 
     Genotype X Sex 0.02 
     Genotype X Treatment <0.01 
Sex X Treatment <0.01 
     Genotype X Treatment X Sex 0.06 
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Figure 3.7: Evoked colorplots and cyclic voltommograms (inlet) for dopamine (left) and 
serotonin (right) in F344/N animals (top) and HIV-1 Tg animals (bottom). 
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Figure 3.8: Evoked dopaminergic potentials for genotype (top) and genotype by treatment 
condition (bottom). Dopamine transmission was found to be impaired in HIV-1 Tg 
animals relative to F344 controls (p<0.05). Escitalopram treatment was not found to 
attenuate dopaminergic deficits in HIV Tg animals. 
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Figure 3.9: Evoked serotonergic potentials for genotype (top) and genotype by treatment 
condition (bottom). Serotonergic transmission was found to be impaired in HIV-1 Tg 
animals relative to F344 controls (p<0.05). Escitalopram treatment was not found to 
attenuate dopaminergic deficits in HIV Tg animals, though treatment did appear to alter 
serotonergic function in F344 controls. 
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CHAPTER 4 
DISCUSSION 
Presently, the effects of escitalopram treatment upon the HIV-1 Tg rat were 
evaluated with a behavioral testing battery and in-vivo electrochemical analysis. 
Globally, escitalopram treatment did not appear to significantly alter behavioral 
functioning in the HIV-1 Tg rat. While treatment did indeed increase overall serotonergic 
transmission in F344/N controls, this effect was not found with respect to HIV-1 Tg 
animals, which persisted to demonstrate impairment despite treatment. 
Though escitalopram did not appear to alter sucrose consumption in either HIV-1 
Tg or F344/N animals, an interesting curvilinear shift in sucrose concentration 
responding occurred in HIV-1 Tg animals. F344/N animals displayed a steady linear 
relationship across increasing sucrose concentrations with higher concentrations of 
sucrose clearly favored. While sucrose concentrations were clearly preferred over water 
in HIV-1 Tg rats, responses to concentrations of 5% sucrose or higher were essentially 
flat-lined, with no clear preference for higher concentrations despite drug treatment. This 
alteration in responding is a departure from previous findings using the HIV-1 Tg rat. 
Indeed, Bertrand (2018) did not find a difference in response to variable sucrose 
concentration between F344 and HIV-1 Tg animals.  
This departure from previous findings may have several alternative explanations. 
First, the curvilinear shift and subsequent flattening of responding in the HIV-1 Tg 
animals may potentially be an effect of mediation by escitalopram treatment. Previously, 
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Bertrand (2018) did not expose animals to any sort of treatment which might 
serve as a mediating factor. Secondly, the present study used a much shorter time period 
for testing sucrose preference. Bertrand (2018) utilized a testing period of one hour while 
the present experiment used a testing window of 30 minutes. This discrepancy may 
potentially explain the difference in findings between these studies, although this is 
highly unlikely. 
Perhaps the most reasonable explanation for the present findings is that Bertrand 
(2018) performed sucrose testing on female rats that were ovariectomized and thus not 
subject to hormonal fluctuations. In the present experiment, female rats had intact ovaries 
and thus normal hormonal function. While research into the effects of hormonal cycling 
upon behavioral testing in rats has been rather sparse, it has been previously found that 
estrus cyclicity does indeed influence anxiety related behaviors (D’Souza and Sadananda, 
2017) and motivated, goal-driven behaviors (Steiner et al., 1981). It is quite probable that 
variation in hormone levels could potentially explain this deviation from previous work.  
Indeed, the present finding that sucrose consumption is impaired across variable 
concentrations is in line with the previous discussion of apathy in the HIV Tg rat, and fits 
with the narrative of apathy and HIV within the clinical literature. Here, we report a 
flattening of response curve across increasing sucrose concentrations. HIV-1 Tg rats did 
not appear to prefer 30% sucrose concentrations any more than they did 5% 
concentrations. These findings are highly suggestive of an apathetic response within the 
transgenic rat, as rodents with intact, healthy motivational systems should most clearly 
prefer higher sucrose concentrations to lower concentrations, with highest preference 
given to the highest concentration. Thus, the present findings strongly support the 
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argument for motivational dysregulation in the HIV-1 Tg rat, though treatment with 
escitalopram failed to attenuate this motivational dysregulation.  
While escitalopram treatment did not appear to performance during the sucrose 
preference task, effects of escitalopram treatment are more clearly seen in the exploration 
based tasks such as the elevated plus maze. Unsurprisingly, multivariate analysis of 
rodent performance across both tasks revealed a significant interaction effect between 
genotype and sex. With respect to antidepressant treatment, it would appear across both 
tasks that escitalopram did indeed improve measures of exploration in both F344 controls 
and in HIV-1 Tg rats. With respect to elevated plus maze trials, total time spent on the 
open arms of the apparatus was increased in animals treated with escitalopram. In fact, 
exploration time for female HIV-1 Tg animals treated with escitalopram was higher than 
total times for each of the other groups. However, it is of note that escitalopram did not 
produce such robust effects in male F344 animals, as such animals treated with 
escitalopram explored less than their placebo treated counterparts. 
Findings from the modified hole board task did not produce such robust effects, 
however, as escitalopram treated animals performed less average nose pokes across the 
trial period than placebo treated animals, with the exception of female F344 rats. HIV-1 
Tg rats treated with escitalopram performed more poorly on the task than placebo treated 
HIV-1 Tg animals. Mirroring findings from the elevated plus maze, F344 males treated 
with escitalopram showed decreased activity relative to placebo treated F344 males. 
While conclusions about the efficacy of escitalopram in improving performance 
in exploration based tasks in HIV-1 Tg rats are difficult to draw from these mixed 
findings, it is clear that anti-depressant treatment was less effective more males, 
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irrespective of genotype. This finding closely mirrors findings from clinical 
antidepressant trials, as males typically show decreased receptiveness to antidepressant 
treatment relative to females, despite the fact that females are far more at risk for the 
development of depression than males (Sramek et al., 2016). While many sex-difference 
based studies were performed for older forms of antidepressants, Khan et al., (2005) 
examined sex differences in response to SSRI treatment across a variety of SSRIs, 
including escitalopram and its r-enantiomer citalopram (tradename Celexa). In this study, 
while the authors argue that SSRI treatment is still a viable option for males suffering 
from depression, the effectiveness of this medication may be much greater for females 
(Khan et al., 2005). 
In a 2016 review, Sramek and colleagues summarize many of the studies 
reporting sex differences with respect to antidepressant function, while no single 
mechanism is responsible for the sex dependent response to antidepressant treatment, 
many factors have been proposed. Of particular interest, the age of onset of depression in 
females is typically during adolescence and may correspond strongly to the onset of 
puberty. Hormonal fluctuations in puberty, menstruation and menopause may potentially 
affect the efficacy of treatment in addition to sex-dependent monoamine functioning. 
Consequently, interactions between serotonin and estrogen may potentially serve as a 
biological basis for variable antidepressant action (Sramek et al., 2016). 
In addition to factors previously discussed Sramek and colleagues (2016) discuss 
factors such as body fat, weight distribution and consequent liver metabolism rates/drug 
clearance rats as underlying the differences between male and female response to 
antidepressants. Moreover, sex dependent factors such as plasma volume, enzymatic 
31 
activity, protein levels and gastric activity may underlie sex dependent responses to 
antidepressant treatment in addition to sociocultural factors such as adherence (Sramek et 
al., 2016). Overall, the present findings of decreased escitalopram efficacy in male rats 
independent of genotype appears to be consistent with the clinical narrative.  
Here, we report significant impairment of both auditory and visual pre-pulse 
inhibition in the HIV-1 Tg rat. These findings follow a consistent narrative within our 
laboratory as such deficits in pre-pulse inhibition in the HIV-1 Tg rat have been 
consistently reported (Moran et al., 2013; McLaurin et al., 2016; McLaurin et al., 2017; 
McLaurin et al., 2017; McLaurin et al., 2018). Although the present study replicates the 
body of previous literature, an effect of escitalopram treatment was not found to attenuate 
deficits in either auditory or visual PPI for HIV-1 Tg animals. However, abnormal 
alterations in PPI across inter-stimulus interval for HIV-1 Tg animals were clearly 
observed. The cause for this disturbance remains unclear, although it was been noted in 
the clinical literature that escitalopram treatment may induce abnormal visual experiences 
which may consequently interfere with visual perception (Lai 2012). Such alteration 
might clearly impede performance on a visual based task. However, escitalopram did not 
alter visual PPI performance in F344/N males. These effects may be due to individual 
variation of response to drug treatment in the HIV-1 Tg rat. Indeed, individual 
differences in the HIV-1 Tg in the variation of response to potential therapeutics has 
previously been described (McLaurin et al., 2018). 
Deficits in pre-pulse inhibition have been previously discussed as a feature of 
non-psychotic major depressive disorder (Perry et al., 2004) and described as a function 
of serotonergic activity (Fletcher et al., 2001).  Patients suffering from depression are 
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hypothesized to have impaired circuitry of cortico-striato-pallido-thalamic pathways 
which regulate PPI- a feature that is also found in schizophrenic patients (Perry et al., 
2004). Although reductions in PPI are slight in depression compared with psychotic 
disorders such as schizophrenia, studies suggest a deficit is indeed present when 
compared with healthy control patients (Perry et al., 2004, Matuso et al., 2017).  Pre-
pulse inhibition represents a translational way to study serotonergic-based deficits which 
likely underlie to high incidence of comorbidity between HIV and depression. However, 
the effect of serotonergic agonists upon PPI is understudied and often inconclusive 
(Martinez and Geyer, 1997; Phillips et al., 2000; Quednow et al., 2004). 
 No differences were found in social interaction for any treatment group. 
Irrespective of genotype, sex or treatment, rodents typically spent the majority of the trail 
period engaged in some form of social interaction. HIV-1 Tg animals displayed no 
impairment in social interaction compared to controls. These findings are in line with 
previous work, given the context of what is known about the relatively healthy growth 
and progression of the HIV-1 Tg rat across its lifespan. No aberrations have been 
reported in healthy growth weight for the HIV-1 Tg rat (Peng et al., 2010; Moran et al., 
2013). Moreover, across several studies, the HIV-1 Tg rat has repeatedly exhibited intact 
sensory and motor function (Peng et al., 2010; McLaurin et al.,2018). Taken together, 
nothing about what is known about the relatively healthy growth and function of the 
transgenic rat would suggest a deficit in social interaction. 
 Anti-depressant treatment is generally understood to produce anxiolytic properties 
in both preclinical (Griebel et al., 1994) and clinical studies (Kent et al., 1998). Despite 
this understanding, previous literature has shown r-citalopram (Lexapro) to actually 
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decrease social interaction in rodent models (Dekeyne et al., 2000 Rodriguez-Porcel et 
al., 2011). Despite the findings of these studies, here we report no global effect of 
escitalopram upon social interaction time. A potential explanation for these findings is 
that in the present study, antidepressant treatment was chronically administered to 
animals with healthy social interaction systems. As previously discussed, no prior 
literature provides an evidentiary basis for why any social impairment would exist in the 
HIV-1 Tg rat. Previous experiments in which antidepressant treatment was found to 
increase social interaction were conducted in animals which had interaction activities 
disrupted by procedures such as social defeat (Griebel et al., 1994). Studies which 
reported r-citalopram as decreasing social interaction administered the treatment to 
animals either as an acute dosage (Dekeyne et al., 2000) or in neonates (Rodriguez-Porcel 
et al., 2011). In the case of acute dosages, it is possible that an immediate increase in 
serotonin levels would elicit adverse effects upon initial administration (Mir and Taylor 
1997; Dekeyne et al., 2000). Moreover, such acute high doses may potentially result in a 
loss of serotonin selectivity, and incorporate adrenergic and dopaminergic transmission, 
thereby producing an initial increase in anxiety behaviors (Dekeyne et al., 2000). Given 
that the present study utilized a chronic treatment protocol in adult rodents unlikely to 
have prior social impairment as a function of intervention such as social defeat, the 
present findings of no effects of escitalopram upon social interaction are unsurprising. 
Here, we report simultaneous decreases in rates of release and reuptake in 
dopamine and serotonin activity in HIV-1 Tg rats relative to F344/N controls, which has 
previously been described by our lab (Denton et al, forthcoming). For both 
neurotransmitters, HIV-1 Tg animals demonstrated impaired release kinetics coupled 
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with a significantly decreased maximal release (Cmax). Moreover, reuptake rates in the 
HIV-1 Tg rat were significantly impaired relative to controls for both dopamine and 
serotonin. Transgene mitigated impairments in serotonin and dopamine function may 
provide a neurological basis for comorbid HIV-1 and clinical depression/apathy. 
The current findings of dopaminergic impairments in the HIV-1 Tg rat are 
consistent with our previous research (Javadi-Paydar et al. 2017), which examined 
reuptake times for DA in the HIV-1 Tg rat using ex vivo striatal brain slices. A marked 
extension in reuptake time for exogenously applied DA was found in the HIV-1 Tg brain 
slices, relative to F344/N slices, further suggesting a role of DAT dysfunction in 
mediating DA kinetics in the HIV-1 Tg rat. Moreover, the present findings are consistent 
with what was reported by Denton et al., (forthcoming), which demonstrated profound 
dysfunction of dopamine and serotonin transmission in the HIV-1 Tg rat using an 
identical FSCV protocol as what is described here. In vitro, the HIV-1 protein Tat inhibits 
vesicular monoamine transporter (VMAT2) function (Midde et al. 2012). VMAT2 plays 
an essential role in the packaging of dopamine and serotonin into synaptic vesicles for 
later release (Caudle et. al 2007, Eiden and Weihe 2011). Thus, a disruption in 
monoamine synthesis and packaging may play a role in present findings of dopamine and 
serotonergic impairments in the HIV-1 Tg rat.  
Dopaminergic functioning in the HIV-1 Tg rat following long-term HIV-1 protein 
exposure is characterized by decreased release, lower peak concentrations, and slowed 
reuptake, which are consistent with in vivo PET imaging studies of the HIV-1 Tg rat 
(Sinharay et al. 2017) and findings in human HIV-1 PET imaging studies (Chang et al. 
2008). In contrast, prior studies using synaptosomal preparations from HIV-1 Tg rats 
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(Zhu et al. 2016; Bertrand et al. 2018) reported increased DA reuptake rates. The 
increased efficiency of synaptosomal DAT function in HIV-1 Tg rats likely reflects a 
compensatory response in surviving synapses to long-term HIV-1 protein exposure.  
Long-term HIV-1 protein exposure (many months to years in the HIV-1 Tg rat, i.e., 
similar to long-term HIV-1 exposure in humans) decreases dopaminergic circuit 
neurotransmission, despite maximal DAT function.  
The repeated finding that cortical serotonergic function is disrupted in the HIV-1 
transgenic rat provides a potential biological basis for the high comorbidity instances of 
HIV-1 and clinical depression in the human population. An estimated 30-60% of HIV-1-
infected persons in the United States will develop symptoms of clinical depression over 
the course of their lifetime (Bhatia and Munjal 2014, Castellon et al. 1998). Given our 
consistent findings of diminished serotonin in the HIV-1 Tg rat and the high rates of 
comorbidity of HIV-1 and depression in the clinical population, a serotonergic treatment 
is a logical candidate to be an effective therapeutic for individuals suffering from 
comorbid HIV and depression. Indeed, in a 2018 meta-analysis, Eschun-Wilson and 
colleagues found that antidepressant therapy was more effective than placebo treatment 
in combating depression across a sample of ten studies. While the authors acknowledge 
this trend, they emphasize that the available evidence is limited and sparse (Eschun-
Wilson et al. 2018). However, before such efficacy can be reliably demonstrated, there is 
a clear need for more mechanistic studies of monoamines in animal models of HIV-1 and 
in the seropositive clinical population. 
Presently, escitalopram treatment was not found to attenuate dopaminergic or 
serotonergic impairment in HIV-1 Tg rats, nor did it alter dopaminergic tone in F344/N 
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rats. However, serotonin functioning in F/344 animals was improved by escitalopram 
treatment, though the effect fell short of statistical significance. Treatment failed to even 
marginally improve serotonergic functioning in HIV-1 Tg animals. These findings 
suggest that proper pharmacological intervention my necessitate an individual differences 
based approach. Indeed, McLaurin (2018) argues the importance in assessing the 
individual differences that occur as a function of heterogeneity within the HIV-1 Tg rat 
when exploring potential treatment avenues. Given that the present findings reveal that 
escitalopram did not improve serotonergic tone in the HIV-1 Tg rat, but increased 
transmission in control rats, perhaps a similar individual differences based approach is 
warranted when exploring potential therapeutics for comorbid HIV and depression. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
The present study examined the therapeutic efficacy of the SSRI antidepressant 
escitalopram in attenuating HIV-1 mitigated deficits in the HIV-1 Tg rat. Each of these 
deficits presents a strong clinical correlate to typical observations among HIV-1 patients 
suffering from comorbid clinical depression. Overall, escitalopram was not found to 
attenuate alterations in motivational response, pre-pulse inhibition or social behavior in 
the HIV-1 Tg rat. Escitalopram did, however, modulated exploratory based behaviors. 
Voltammetric analysis revealed that while escitalopram did indeed alter serotonergic 
function globally, it did not appear to alter transgene mediated deficits in either 
serotonergic or dopaminergic functioning. Thus, preliminary investigations yield little 
evidence in support of escitalopram as an effective therapeutic for HIV-1 comorbid 
depression. This is unsurprising given what is known about the widely variable nature of 
antidepressant action. 
Given what is known about individual response to drug treatment in the HIV-1 Tg 
rat, future efforts will be targeted toward developing more conclusive statistical models 
that will be able to further elucidate the actions of escitalopram within the transgenic rat 
at an individual level. SSRI medication is known to have a highly variable range of 
efficacy with many factors contributing to its global function. Through analysis of 
individual variation and response to escitalopram in the HIV-1 Tg rat, targeted 
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therapeutics for HIV-1 seropositive patients suffering from comorbid clinical 
depression may perhaps be developed to attenuate depressive symptoms and hopefully 
restore normal emotive regulation. These treatments, in combination with adherence to 
cART treatment, will hopefully serve to improve overall quality of life for individuals 
suffering from HIV in the post-cART era. While developments in the efficacy of 
antiretroviral treatment have indeed served to increase the prospects of living with HIV, 
significant impairments such as HIV associated neurocognitive disorders and clinical 
depression continue to impede the prospects of living with the disease, thus necessitating 
the need for targeted therapeutics to treat those symptoms which remain present
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